AAM
CLVS

Aberdeen Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Aberdeen Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$549K Buy
+5,863
New +$359K ﹤0.01% 717

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Aberdeen Asset Management's CLVS Position: Q2 2017 in Review

Aberdeen Asset Management opened a new position in Clovis Oncology, Inc. (CLVS) in Q2 2017: 5,863 shares worth $549K. The stake represents ﹤0.01% of the portfolio and ranks #717 among its holdings.

271 funds tracked by Wall St. Rank hold CLVS as of Q2 2017.

  • Aberdeen Asset Management held 5,863 shares of Clovis Oncology, Inc. worth $549K as of Q2 2017.
  • Clovis Oncology, Inc. was a new Aberdeen Asset Management position in Q2 2017.
  • Clovis Oncology, Inc. made up ﹤0.01% of Aberdeen Asset Management's portfolio in Q2 2017, its #717 holding.
  • 271 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.